Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients

Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients

<i>Background:</i> The selection of women with hormone receptor-positive (HR+) early breast cancer (EBC) at high risk of relapse after five years (yrs.) of adjuvant aromatase inhibitors (AIs) is crucial, as the benefit of extending AIs is counterbalanced by toxicity. We developed a clini...

Full description

Bibliographic Details
Main Authors: Camille Moreau-Bachelard, Loïc Campion, Marie Robert, Olivier Kerdraon, Céline Renaudeau, Maud Aumont, Jean-Marc Classe, Mario Campone, Jean-Sébastien Frénel
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
early breast cancer
hormone receptor
positive
late recurrence
Online Access:https://www.mdpi.com/2072-6694/12/12/3725

Internet

https://www.mdpi.com/2072-6694/12/12/3725

Similar Items